Repare Therapeutics (NASDAQ:RPTX) Shares Down 0.6% - Time to Sell?

Key Points

• Repare Therapeutics' stock fell 0.6% to $1.71 with a significant drop in trading volume, indicating potential investor hesitance.
• Wall Street analysts have upgraded the stock from a "sell" to a "hold" rating, with an average price target of $4.50, reflecting cautious optimism.
• Despite a reported revenue of only $0.25 million for the last quarter, Repare Therapeutics exceeded EPS expectations, signaling some resilience in its financial performance.

Shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) dropped 0.6% on Tuesday . The company traded as low as $1.71 and last traded at $1.71. Approximately 29,145 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 90,915 shares. The stock had previously closed at $1.72.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Repare Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $4.50.

Repare Therapeutics Stock Performance

The stock has a market cap of $73.46 million, a PE ratio of -0.66 and a beta of 0.94. The firm has a 50-day moving average price of $1.61 and a 200-day moving average price of $1.40.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.17. The firm had revenue of $0.25 million for the quarter, compared to analysts' expectations of $2.50 million. As a group, sell-side analysts anticipate that Repare Therapeutics Inc. will post -2.04 EPS for the current fiscal year.

Institutional Trading of Repare Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC increased its holdings in shares of Repare Therapeutics by 65.5% in the 4th quarter. Millennium Management LLC now owns 170,959 shares of the company's stock worth $224,000 after purchasing an additional 67,638 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in Repare Therapeutics by 100.0% during the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock valued at $197,000 after purchasing an additional 100,000 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock valued at $624,000 after buying an additional 168,230 shares during the period. Quinn Opportunity Partners LLC bought a new position in Repare Therapeutics in the second quarter valued at about $56,000. Finally, XTX Topco Ltd bought a new position in shares of Repare Therapeutics in the 2nd quarter worth approximately $60,000. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.